Retained Lead Fragments in Superior Vena Cava and Early Post-Transplant Outcomes: A Single Center Preliminary Retrospective Study

<b>Background/Objectives</b>: Retained fragments of cardiovascular implantable electronic device (CIED) leads are frequently observed after orthotopic heart transplantation (OHT), but their clinical relevance remains unclear. <b>Methods</b>: We conducted a single-center, retrospective study of 179 adult patients who underwent OHT between January 2022 and January 2025. Post-transplant imaging was used to identify retained lead fragments. Patients were grouped based on the presence or absence of retained leads. The primary endpoint was all-cause mortality at 30, 90, and 150 days post-transplant. Survival analysis was performed using Kaplan-Meier estimates and Cox proportional hazards modeling. <b>Results</b>: Among 112 patients with pre-transplant CIEDs, 18 (16%) had retained intravascular lead fragments. These patients had significantly lower survival at 30 days (66.7% vs. 94.7%), 90 days (61.1% vs. 90.3%), and 150 days (55.0% vs. 83.5%) compared to those without retained fragments (log-rank <i>p</i> = 0.002). The presence of retained leads was independently associated with increased mortality (HR: 3.71; 95% CI: 1.55-8.84; <i>p</i> = 0.003), even after adjusting for potential confounders. <b>Conclusions</b>: Retained CIED lead fragments are independently associated with higher early post-transplant mortality. These findings support the need for individualized intraoperative strategies to mitigate hardware-related risks in high-risk transplant candidates.